Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Dement Neuropsychol ; 15(1): 51-59, 2021.
Article in English | MEDLINE | ID: mdl-33907597

ABSTRACT

Pharmacological treatments for mild cognitive impairment (MCI), are lacking, and alternative approaches have been implemented, including cognitive training (CT). OBJECTIVE: To determine the impact of CT on cognitive and quality of life measures in patients with Parkinson's disease (PD) who were seen a hospital neurorehabilitation program. METHODS: Thirty-nine individuals with MCI-PD, according to the Movement Disorder Society, were randomly distributed into two groups: experimental and control group, matched for demographic and clinical characteristics. Both groups were assessed for cognition and quality of life at the beginning of the study and at the end of the intervention protocol. The following instruments were used to assess cognition and quality of life: Addenbrooke's Cognitive Examination III, Digit Span, Trail Making Test (TMT, A and B) and Parkinson disease quality of life questionnaire. The experimental group (EG) engaged in CT, whereas the control group (CG) underwent activities of the general rehabilitation program. RESULTS: No baseline evaluation differences were found. Intergroup analysis showed differences in measures, such as total score (1.977, p=0.0480) and visuospatial domain (-2.636, p=0.0084) of the ACE-III, with the EG performing better, in addition to better performance in TMT-B mistakes (-1.928, p=0.0439). Intragroup analysis revealed that the EG showed significant improvement in almost all the cognitive variables, well as in self-reported quality of life (total score and mobility, activities of daily living, body discomfort dimensions). CONCLUSIONS: Engagement in cognitive activities was associated with better cognitive abilities in PD-MCI. Future studies should consider the long-term effect of this type of intervention and impact on functional activities.


A falta de evidência de tratamentos farmacológicos, especificamente para pacientes com comprometimento cognitivo leve na doença de Parkinson (CCL-DP), leva à implementação de abordagens alternativas, incluindo a reabilitação cognitiva. OBJETIVO: Determinar o impacto do treino cognitivo (TC) em medidas cognitivas e da qualidade de vida em pacientes com DP, que participavam de um programa de reabilitação neurológica hospitalar. MÉTODOS: Total de 39 indivíduos com CCL-DP, de acordo com a Sociedade de Distúrbios do Movimento, foram distribuídos aleatoriamente em dois grupos: experimental e controle, pareados por características demográficas e clínicas. Ambos os grupos foram avaliados quanto à cognição e qualidade de vida no início do estudo e ao final do protocolo de intervenção. Os seguintes instrumentos foram utilizados para avaliar a cognição e a qualidade de vida: Exame Cognitivo III de Addenbrooke, teste de dígitos, TMT (A e B) e questionário de qualidade de vida da doença de Parkinson. O grupo experimental foi submetido ao treino cognitivo, ao passo que o grupo controle passou por atividades do programa de reabilitação. RESULTADOS: Não foram encontradas diferenças na avaliação basal. A análise intergrupo mostrou diferenças em medidas, como escore total (1,977, p=0,0480) e domínio visuoespacial (-2,636, p=0,0084) da ACE-III, tendo o grupo experimental melhor desempenho, além de desempenho superior em TMT-B erros (-1,928, p=0,0439). A análise intragrupo revelou que o grupo experimental mostrou melhora significativa em quase todas as variáveis cognitivas, assim como na percepção de qualidade de vida (escore total e dimensões de mobilidade, atividades da vida diária e desconforto corporal). CONCLUSÕES: O envolvimento em atividades cognitivas foi associado a melhores habilidades cognitivas em pacientes com CCL-DP. Estudos futuros devem considerar o efeito a longo prazo desse tipo de intervenção e o impacto nas atividades funcionais.

2.
Dement. neuropsychol ; 15(1): 51-59, Jan.-Mar. 2021. tab
Article in English | LILACS | ID: biblio-1286183

ABSTRACT

ABSTRACT. Pharmacological treatments for mild cognitive impairment (MCI), are lacking, and alternative approaches have been implemented, including cognitive training (CT). Objective: To determine the impact of CT on cognitive and quality of life measures in patients with Parkinson's disease (PD) who were seen a hospital neurorehabilitation program. Methods: Thirty-nine individuals with MCI-PD, according to the Movement Disorder Society, were randomly distributed into two groups: experimental and control group, matched for demographic and clinical characteristics. Both groups were assessed for cognition and quality of life at the beginning of the study and at the end of the intervention protocol. The following instruments were used to assess cognition and quality of life: Addenbrooke's Cognitive Examination III, Digit Span, Trail Making Test (TMT, A and B) and Parkinson disease quality of life questionnaire. The experimental group (EG) engaged in CT, whereas the control group (CG) underwent activities of the general rehabilitation program. Results: No baseline evaluation differences were found. Intergroup analysis showed differences in measures, such as total score (1.977, p=0.0480) and visuospatial domain (-2.636, p=0.0084) of the ACE-III, with the EG performing better, in addition to better performance in TMT-B mistakes (-1.928, p=0.0439). Intragroup analysis revealed that the EG showed significant improvement in almost all the cognitive variables, well as in self-reported quality of life (total score and mobility, activities of daily living, body discomfort dimensions). Conclusions: Engagement in cognitive activities was associated with better cognitive abilities in PD-MCI. Future studies should consider the long-term effect of this type of intervention and impact on functional activities.


RESUMO. A falta de evidência de tratamentos farmacológicos, especificamente para pacientes com comprometimento cognitivo leve na doença de Parkinson (CCL-DP), leva à implementação de abordagens alternativas, incluindo a reabilitação cognitiva. Objetivo: Determinar o impacto do treino cognitivo (TC) em medidas cognitivas e da qualidade de vida em pacientes com DP, que participavam de um programa de reabilitação neurológica hospitalar. Métodos: Total de 39 indivíduos com CCL-DP, de acordo com a Sociedade de Distúrbios do Movimento, foram distribuídos aleatoriamente em dois grupos: experimental e controle, pareados por características demográficas e clínicas. Ambos os grupos foram avaliados quanto à cognição e qualidade de vida no início do estudo e ao final do protocolo de intervenção. Os seguintes instrumentos foram utilizados para avaliar a cognição e a qualidade de vida: Exame Cognitivo III de Addenbrooke, teste de dígitos, TMT (A e B) e questionário de qualidade de vida da doença de Parkinson. O grupo experimental foi submetido ao treino cognitivo, ao passo que o grupo controle passou por atividades do programa de reabilitação. Resultados: Não foram encontradas diferenças na avaliação basal. A análise intergrupo mostrou diferenças em medidas, como escore total (1,977, p=0,0480) e domínio visuoespacial (-2,636, p=0,0084) da ACE-III, tendo o grupo experimental melhor desempenho, além de desempenho superior em TMT-B erros (-1,928, p=0,0439). A análise intragrupo revelou que o grupo experimental mostrou melhora significativa em quase todas as variáveis cognitivas, assim como na percepção de qualidade de vida (escore total e dimensões de mobilidade, atividades da vida diária e desconforto corporal). Conclusões: O envolvimento em atividades cognitivas foi associado a melhores habilidades cognitivas em pacientes com CCL-DP. Estudos futuros devem considerar o efeito a longo prazo desse tipo de intervenção e o impacto nas atividades funcionais.


Subject(s)
Humans , Parkinson Disease , Quality of Life , Rehabilitation , Cognition
3.
J Child Neurol ; 35(3): 202-207, 2020 03.
Article in English | MEDLINE | ID: mdl-31718421

ABSTRACT

OBJECTIVE: To describe the 2-year neurodevelopmental outcome in children with cerebral palsy associated with congenital Zika (CZ) and explore variables associated with a more severe presentation. METHODS: Data on 69 children with cerebral palsy associated with CZ, followed in a neurorehabilitation hospital, who consecutively attended the neurodevelopmental assessment at 2 years of age, were collected. Bayley III Scales of Infant and Toddler Development, Hammersmith Infant Neurological Examination, and Gross Motor Function Classification System were used for the outcome evaluation. Descriptive and inferential statistical analysis were performed. RESULTS: The median age at follow-up was of 24.0 (23-32) months. Only 3 (4.3%) children were not microcephalic. The majority presented with bilateral (94.2%), spastic (100.0%), Gross Motor Function Classification System grade IV or V (92.8%) cerebral palsy, epilepsy (73.1%), extremely low performances on cognitive (94.2%), language (95.7%), and motor (95.7%) Bayley-III Scales of Infant and Toddler Development Test scores. The median Hammersmith Infant Neurological Examination score was of 21.0 (range 9-75). There was a correlation between birth head circumference with the cognitive (r = 0.3, P < .01), language (r = 0.3, P < .01), and motor (r = 0.3, P < .01) Bayley-III Scales of Infant and Toddler Development Test scores, as well as with the Hammersmith Infant Neurological Examination score (r = 0.2, P < .03). An association was observed between an inferior median Hammersmith Infant Neurological Examination score with congenital microcephaly (P = .04), arthrogryposis (P = .02), and epilepsy in the first year (P < .01). CONCLUSION: Cerebral palsy related to CZ presents with a severe global impairment at a 2-year follow-up. Birth head circumference, arthrogryposis, and early epilepsy are associated with a worse outcome and may be considered as prognostic markers. These findings are important for the neurorehabilitation planning, parents' guiding, and future prognostic studies.


Subject(s)
Cerebral Palsy/complications , Developmental Disabilities/complications , Epilepsy/complications , Neurologic Examination/methods , Zika Virus Infection/complications , Cephalometry/statistics & numerical data , Child, Preschool , Cohort Studies , Female , Follow-Up Studies , Humans , Infant , Male , Prospective Studies
4.
Brain Dev ; 41(7): 587-594, 2019 Aug.
Article in English | MEDLINE | ID: mdl-30914212

ABSTRACT

OBJECTIVE: To describe the neurological and neurodevelopmental features at 1 year of age in children with cerebral palsy (CP) related to probable congenital Zika (CZ), followed in a referral neurorehabilitation hospital. METHODS: Data on 82 children with CP associated with probable CZ, who consecutively attended the neurodevelopmental and neurological assessment around one year of age, were collected. For neurodevelopmental evaluation, Bayley-III Scales of Infant and Toddler Development was used. Descriptive statistical analysis was performed. RESULTS: The children were admitted into the rehabilitation program at a young age (mean age: 4.8 months, SD 3.1), followed beyond the first year of life (mean age of follow up: 13.2 months, SD 2.1), born to young mothers (mean age: 28.1 years, SD 5.9), in their first pregnancy (62.2%). The majority had severe congenital microcephaly (62.0%), spastic CP (96.3%), epilepsy (63.4%), absent expected postural reactions (93.2%), abnormal persistence of primitive reflexes (94.7%), and severe neuroimaging abnormalities, predominantly calcifications (97.6%). Extremely low performances on cognitive (95.1%), language (97.6%) and motor (97.6%) developmental composite scores were observed. There was a correlation between the cognitive score with the birth head circumference (HC) (r = 0.3, p = 0.01) and with the follow up HC (r = 0.4, p < 0.01), as well as between the follow up HC with the motor score (r = 0.2, p = 0.03). CONCLUSION: Congenital Zika may be associated with a severe form of CP, mainly bilateral spastic, with a severe global neurodevelopmental impairment and early signs of a poor prognosis for independent walking. Head circumference may be a prognostic marker among those children. These results may help establish goals for the rehabilitation program and identify priority health services.


Subject(s)
Cerebral Palsy/physiopathology , Cerebral Palsy/virology , Zika Virus Infection/physiopathology , Zika Virus/isolation & purification , Cerebral Palsy/complications , Cerebral Palsy/diagnostic imaging , Developmental Disabilities/diagnosis , Developmental Disabilities/diagnostic imaging , Developmental Disabilities/virology , Female , Gestational Age , Humans , Infant , Infant, Newborn , Male , Microcephaly/complications , Microcephaly/diagnostic imaging , Microcephaly/virology , Neurodevelopmental Disorders/diagnosis , Neurodevelopmental Disorders/diagnostic imaging , Neurodevelopmental Disorders/physiopathology , Neurodevelopmental Disorders/virology , Neuroimaging/methods , Neurologic Examination/methods , Zika Virus Infection/diagnostic imaging , Zika Virus Infection/virology
5.
Clin Case Rep ; 6(11): 2053-2056, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30455890

ABSTRACT

We report a case of a Brazilian child born in 2011 with congenital Zika syndrome phenotype. Zika virus (ZIKV) may have been circulating in Brazil more than 4 years before the outbreak. ZIKV infection might be considered in children with this phenotype even without known circulation of ZIKV.

6.
Mult Scler Relat Disord ; 9: 125-8, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27645359

ABSTRACT

PURPOSE: Comorbidity of celiac disease with demyelinating diseases of the central nervous system has been reported since the 1960s. The objective of this study was to determine the serological prevalence of celiac disease in the largest series of patients diagnosed with multiple sclerosis, neuromyelitis optica, or myelitis. METHODS: A prevalence study was conducted with patients evaluated at Sarah Network of Rehabilitation Hospitals between March 2012 and September 2013. They were previously diagnosed with multiple sclerosis, neuromyelitis optica, or idiopathic myelitis. The serum levels of antibodies against tissue transglutaminase and endomysium were assessed. RESULTS: Of the 379 patients evaluated, 249 (65.70%) were diagnosed with multiple sclerosis, 37 (9.56%) with neuromyelitis optica, and 96 (24.54%) with idiopathic myelitis. Two patients (0.53%), one with multiple sclerosis and other with myelitis, tested positive for both antibodies. CONCLUSION: Our study do not confirm the relationship between celiac serological antibodies with multiple sclerosis, neuromyelitis optica and inflammatory myelitis of an unknown etiology.


Subject(s)
Celiac Disease/epidemiology , Multiple Sclerosis/epidemiology , Myelitis/epidemiology , Neuromyelitis Optica/epidemiology , Adolescent , Adult , Brazil/epidemiology , Celiac Disease/blood , Female , Humans , Male , Middle Aged , Multiple Sclerosis/blood , Myelitis/blood , Neuromyelitis Optica/blood , Prevalence , Retrospective Studies , Young Adult
7.
Arq Neuropsiquiatr ; 67(1): 62-8, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19330214

ABSTRACT

We evaluated the safety and effectiveness of botulinum toxin A (BoNT/A) in the treatment of spasticity in 20 children with spastic diplegic cerebral palsy (CP). All the patients received injections in the gastrocnemius and soleus, and 15 received injections in the adductors. The total dose varied from 70 to 140 U (99.75+/-16.26 U), or 7.45+/-2.06 U/kg per patient. The treatment improved the patients' walking and gait pattern significantly. There was also a significant alteration in the heel-ground distance and increased motion of the ankle joint. These structural changes in the feet were sustained until the end of the follow-up, although the same was not observed for the functional parameters. Three patients complained of weakness in the lower limbs. In conclusion, BoNT/A is safe and effective when used in a single session of injections and produces a sustained structural modification of the lower limbs. However, functional changes are temporary and are only observed during the peak effect of the drug.


Subject(s)
Botulinum Toxins, Type A/administration & dosage , Cerebral Palsy/drug therapy , Neuromuscular Agents/administration & dosage , Adolescent , Cerebral Palsy/complications , Child , Child, Preschool , Female , Follow-Up Studies , Gait/drug effects , Humans , Infant , Lower Extremity/physiopathology , Male , Muscle Spasticity/drug therapy , Muscle Tonus/drug effects , Statistics, Nonparametric , Treatment Outcome
8.
Arq. neuropsiquiatr ; 67(1): 62-68, Mar. 2009. graf, tab
Article in English | LILACS | ID: lil-509110

ABSTRACT

We evaluated the safety and effectiveness of botulinum toxin A (BoNT/A) in the treatment of spasticity in 20 children with spastic diplegic cerebral palsy (CP). All the patients received injections in the gastrocnemius and soleus, and 15 received injections in the adductors. The total dose varied from 70 to 140 U (99.75±16.26 U), or 7.45±2.06 U/kg per patient. The treatment improved the patients' walking and gait pattern significantly. There was also a significant alteration in the heel-ground distance and increased motion of the ankle joint. These structural changes in the feet were sustained until the end of the follow-up, although the same was not observed for the functional parameters. Three patients complained of weakness in the lower limbs. In conclusion, BoNT/A is safe and effective when used in a single session of injections and produces a sustained structural modification of the lower limbs. However, functional changes are temporary and are only observed during the peak effect of the drug.


Para avaliação da segurança e eficácia do tratamento com toxina botulínica A (TB-A) na espasticidade na paralisia cerebral (PC), foram selecionadas 20 crianças com a forma diplegia espástica. Todos os pacientes receberam injeções nos gastrocnêmios e sóleos, 15 receberam doses nos adutores da coxa. A dose total variou de 70 a 140 Us (99,75±16,26 U), 7,45±2,06 U/Kg por paciente. O tratamento com a TB-A melhorou significativamente a deambulação e o padrão de marcha. Houve também significativa alteração da distância tornozelo-solo e aumento da amplitude de movimento da articulação do tornozelo. Essas mudanças estruturais dos pés se mantiveram até o final do acompanhamento. O mesmo não foi observado com parâmetros funcionais. Três pacientes apresentaram fraqueza em membros inferiores. Conclui-se que a TB-A, em uma única aplicação, é segura e eficaz. Há modificação sustentada da estrutura motora dos membros inferiores, porém mudanças funcionais são temporárias, durante o pico de ação do medicamento.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Botulinum Toxins, Type A/administration & dosage , Cerebral Palsy/drug therapy , Neuromuscular Agents/administration & dosage , Cerebral Palsy/complications , Follow-Up Studies , Gait/drug effects , Lower Extremity/physiopathology , Muscle Spasticity/drug therapy , Muscle Tonus/drug effects , Statistics, Nonparametric , Treatment Outcome
9.
Arq Bras Cardiol ; 88(5): 514-20, 2007 May.
Article in English, Portuguese | MEDLINE | ID: mdl-17589624

ABSTRACT

OBJECTIVES: To determine if there are evidences of a causal relation between patent foramen ovale (PFO) x cryptogenic ischemic stroke (IS) in the young population and to analyze this relation in terms of causal criteria. METHODS: A total of 168 young patients with IS was retrospectively evaluated and divided into two groups: cryptogenic and with a defined cause. As a routine procedure, the patients underwent investigation of the PFO by means of transesophageal echocardiogram and/or transcranial Doppler sonography, both of them associated with the bubble test. Multivariate analysis was performed after demonstration of univariate statistical association between PFO x IS. RESULTS: After multivariate analysis, the association between PFO x cryptogenic IS was still statistically significant with odds ratio (adjusted OR = 3.3; 95% CI: 1.5-7.4). The total number of cerebral lesions also presented a significant association with cryptogenic IS (adjusted OR = 0.4; 95% CI: 0.2-0.9). The association between PFO and cryptogenic IS met all the causality criteria. CONCLUSION: The causal relation between PFO and cryptogenic IS in the young population is highly probable. This fact should be considered in the therapeutic decision.


Subject(s)
Foramen Ovale, Patent/complications , Stroke/etiology , Adolescent , Adult , Female , Foramen Ovale, Patent/diagnosis , Humans , Male , Middle Aged , Multivariate Analysis , Retrospective Studies , Risk Factors
10.
Arq. bras. cardiol ; 88(5): 514-520, maio 2007. tab
Article in Portuguese | LILACS | ID: lil-453040

ABSTRACT

OBJETIVOS: Determinar se há evidências de uma relação causal entre forame oval patente (FOP) e acidente vascular cerebral isquêmico (AVCI) criptogênico em jovens. Analisar essa relação à luz dos critérios de causalidade. MÉTODOS: Avaliaram-se, retrospectivamente, 168 pacientes jovens com AVCI, divididos em dois grupos: criptogênico e de causa definida. Como parte da rotina, os pacientes foram submetidos a pesquisa de FOP por ecocardiograma transesofágico e/ou Doppler transcraniano, ambos associados ao teste de bolhas. Demonstrada a associação estatística univariada entre FOP e AVCI, procedeu-se a análise multivariada. RESULTADOS: Após análise multivariada, a associação FOP e AVCI criptogênico mostrou-se ainda estatisticamente significante, com razão de chance (RCajustada de 3,3 (IC95 por cento 1,5-7,4). O número total de lesões no encéfalo também apresentou associação significativa com o AVCI criptogênico (RCajustada= 0,4 IC95 por cento 0,2-0,9). A associação FOP e AVCI criptogênico satisfez todos os critérios de causalidade. CONCLUSÃO: A relação causal entre o FOP e o AVCI criptogênico em jovens é altamente provável. Esse fato deve ser considerado na decisão terapêutica.


OBJECTIVES: To determine if there are evidences of a causal relation between patent foramen ovale (PFO) x cryptogenic ischemic stroke (IS) in the young population and to analyze this relation in terms of causal criteria. METHODS: A total of 168 young patients with IS was retrospectively evaluated and divided into two groups: cryptogenic and with a defined cause. As a routine procedure, the patients underwent investigation of the PFO by means of transesophageal echocardiogram and/or transcranial Doppler sonography, both of them associated with the bubble test. Multivariate analysis was performed after demonstration of univariate statistical association between PFO x IS. RESULTS: After multivariate analysis, the association between PFO x cryptogenic IS was still statistically significant with odds ratio (adjusted OR = 3.3; 95 percent CI: 1.5-7.4). The total number of cerebral lesions also presented a significant association with cryptogenic IS (adjusted OR = 0.4; 95 percent CI: 0.2-0.9). The association between PFO and cryptogenic IS met all the causality criteria. CONCLUSION: The causal relation between PFO and cryptogenic IS in the young population is highly probable. This fact should be considered in the therapeutic decision.


Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Foramen Ovale, Patent/complications , Stroke/etiology , Foramen Ovale, Patent/diagnosis , Multivariate Analysis , Retrospective Studies , Risk Factors
11.
J Clin Rheumatol ; 13(2): 85-6, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17414536

ABSTRACT

A multiple sclerosis-like syndrome, also called lupoid sclerosis for having some lupus characteristics, has been described in a few reports. Recently, antiphospholipid antibodies have been demonstrated in patients with this syndrome, suggesting that they can participate in the etiopathogenic process, which can have therapeutic implications. We report the case of a patient previously diagnosed with multiple sclerosis who later presented with ANA positivity and antiphospholipid antibodies, livedo reticularis, and deep venous thrombosis, leading her to be characterized as having lupoid sclerosis. The patient was anticoagulated. Antiphospholipid antibodies may be involved in the pathogenesis of lupoid sclerosis.


Subject(s)
Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/immunology , Multiple Sclerosis/immunology , Adult , Antibodies, Antinuclear/blood , Antiphospholipid Syndrome/complications , Female , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/immunology , Multiple Sclerosis/complications
12.
Rev. bras. ecocardiogr ; 19(1): 15-19, jan.-mar. 2006. ilus, tab, graf
Article in Portuguese | LILACS | ID: lil-427567

ABSTRACT

Estima-se que 40 por cento dos acidentes vasculares cerebrais isquêmicos (AVC) sejam classificados como criptogênicos. Essa cifra costuma ser maior nos pacientes jovens. A embolia paradoxal, cujo forame oval patente (FOP) é o principal exemplo, pode ser responsável por uma parcela desses casos. Entre janeiro de 2004 e novembro de 2004, 168 pacientes com diagnóstico de AVCI, entre 15 e 45 anos de idade, admitidos em unidades da Rede Sarah de hospitais foram admitidos, além da avaliação de rotina, a pesquisa de FOP com ecodopplercardiograma transesofágico e/ou Doppler transcraniano, ambos associados ao teste de bolhas.Usando a combinação dos dois métodos a prevalência da FOP em toda a amostra foi de 28 por cento (IC95 por cento 21,3-35,4).Nos pacientes com AVCI criptogênico essa prevalência sobe para 40 por cento e no grupo com etiologia definida foi de apenas 15 por cento, configurando uma razão de chances de 3,7 (IC 95 por cento 1,8-7,9). Esses resultados apontam para a necessidade de se considerar a possibilidade de embolia paradoxal na etiologia do AVCI criptogênico em pacientes jovens.


Subject(s)
Adult , Male , Female , Humans , Stroke/complications , Stroke/mortality , Heart Septal Defects, Atrial/complications , Echocardiography, Transesophageal/methods , Heart Septum/anatomy & histology , Ultrasonography, Doppler, Transcranial
13.
Arq. neuropsiquiatr ; 63(4): 1047-1053, dez. 2005. tab, graf
Article in Portuguese | LILACS | ID: lil-419018

ABSTRACT

OBJETIVO: Avaliar a freqüência de forame oval patente (FOP) em pacientes com acidente cerebrovascular isquêmico (AVCI) criptogênico ou de causa definida, investigados com doppler transcraniano (DTC) e ecocardiograma transesofágico. Paralelamente, examinar a validade diagnóstica do primeiro, comparado ao segundo método. MÉTODO: Retrospectivamente, foram estudados 124 pacientes (< 51 anos), vítimas de AVCI, submetidos a DTC e ou ecocardiograma transesofágico. Os pacientes foram classificados em dois grupos: com ou sem AVCI criptogênico. RESULTADOS: Encontramos importante associação entre AVCI criptogênico e FOP (razão de chance de 4,3; IC95 por cento 1,7 -10,7). Foram diagnosticados apenas 5 casos de aneurisma do septo interatrial entre aqueles com FOP, todos classificados como AVCI criptogênico. Tanto a sensibilidade, especificidade e os valores preditivos positivo e negativo exibiram valores superiores a 85 por cento, semelhantes, pelo menos com base nos intervalos de confiança. CONCLUSÃO: Constatamos, pela primeira vez em nosso meio, forte associação entre AVCI criptogênico e FOP. O DTC é importante recurso diagnóstico nesse contexto, já que sua validade foi considerada muito boa, podendo ser útil no rastreamento de fontes emboligênicas, particularmente alterações do septo atrial. Uma investigação minuciosa desses casos se impõe, notadamente pela perspectiva de fechamento do shunt intracardíaco.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Brain Ischemia/etiology , Heart Septal Defects, Atrial , Echocardiography, Transesophageal , Epidemiologic Methods , Heart Septal Defects, Atrial/complications , Ischemic Attack, Transient/etiology , Ultrasonography, Doppler, Transcranial
14.
Arq Neuropsiquiatr ; 63(4): 1047-53, 2005 Dec.
Article in Portuguese | MEDLINE | ID: mdl-16400427

ABSTRACT

OBJECTIVE: To verify the frequency of patent foramen ovale (PFO) among patients with ischemic stroke (cryptogenic or with a known cause) investigated by transcranial doppler (TCD) and transesophageal echocardiography. Secondarily, to determine the diagnostic validity of the former, compared with the later method. METHOD: Retrospectively, 124 patients (<51 years old) with ischemic stroke were submitted to TCD and or transesophageal echocardiography. The patients were classified as cryptogenic stroke or not. RESULTS: We could found an important association between cryptogenic ischemic stroke and PFO (odds ratio 4.3--CI 95% 1.7-10.7). Only five cases of interatrial septal aneurysm were diagnosed among patients with PFO. Sensitivity, specificity and positive and negative predictive values exhibited values upper of 85%, equivalents, at least based on confidence intervals. CONCLUSION: We could determine, for the first time in our country, a strong association between cryptogenic ischemic stroke and PFO. The TCD is a valuable diagnostic resource in this context since its validity was considered excellent. A detailed investigation in these cases should always be done due to the possibility of FOP closure.


Subject(s)
Brain Ischemia/etiology , Heart Septal Defects, Atrial/diagnostic imaging , Adult , Echocardiography, Transesophageal , Epidemiologic Methods , Female , Heart Septal Defects, Atrial/complications , Humans , Ischemic Attack, Transient/etiology , Male , Middle Aged , Ultrasonography, Doppler, Transcranial
16.
Arq. neuropsiquiatr ; 59(3B): 784-789, Sept. 2001. ilus, tab
Article in English | LILACS | ID: lil-295849

ABSTRACT

Reversible posterior leucoencephalopathy syndrome (RPLS) has previously been described in patients who have renal insufficiency, eclampsia, hypertensive encephalopathy and patients receiving immunosuppressive therapy. The mechanism by which immunosuppressive agents can cause this syndrome is not clear, but it is probably related with cytotoxic effects of these agents on the vascular endothelium. We report eight patients who received cyclosporine A (CSA) after allogeneic bone marrow transplantation or as treatment for severe aplastic anemia (SSA) who developed posterior leucoencephalopathy. The most common signs and symptoms were seizures and headache. Neurological dysfunction occurred preceded by or concomitant with high blood pressure and some degree of acute renal failure in six patients. Computerized tomography studies showed low-density white matter lesions involving the posterior areas of cerebral hemispheres. Symptoms and neuroimaging abnormalities were reversible and improvement occurred in all patients when given lower doses of CSA or when the drug was withdrawn. RPLS may be considered an expression of CSA neurotoxicity


Subject(s)
Humans , Child , Adolescent , Adult , Middle Aged , Male , Female , Bone Marrow Transplantation/adverse effects , Cyclosporine/adverse effects , Graft vs Host Disease/prevention & control , Immunosuppressive Agents/adverse effects , Nervous System Diseases/etiology , Acute Kidney Injury , Brain Diseases/etiology , Brain/pathology , Creatinine/blood , Cyclosporine/blood , Follow-Up Studies , Headache/etiology , Hypertension/etiology , Kidney Failure, Chronic/etiology , Myelodysplastic Syndromes/prevention & control , Syndrome
17.
Arq. neuropsiquiatr ; 59(1): 97-100, Mar. 2001. tab
Article in Portuguese | LILACS | ID: lil-284246

ABSTRACT

A distonia laríngea (disfonia espasmódica) é distúrbio do movimento caracterizado por contrações involuntárias da musculatura laríngea envolvida no processo de vocalização. A utilização da toxina botulínica no tratamento da distonia laríngea trouxe consideráveis benefícios clínicos. Descrevemos os resultados preliminares do uso terapêutico da toxina botulínica no tratamento da distonia laríngea em 12 pacientes. Após investigação clínica, os pacientes foram submetidos a videolaringoestroboscopia para confirmação diagnóstica e as injeções de toxina botulínica foram realizadas através de punção da membrana cricotireóidea em direção ao músculo tireoaritenóideo, com uso de eletromiografia. A maioria dos pacientes submetidos ao tratamento com toxina botulínica apresentou melhora significativa da distonia laríngea (83 por cento dos casos), com duração média do efeito de quatro meses, sem efeitos colaterais significativos


Subject(s)
Humans , Male , Female , Aged , Middle Aged , Adult , Anti-Dyskinesia Agents/therapeutic use , Botulinum Toxins/therapeutic use , Dystonia/drug therapy , Laryngeal Diseases/drug therapy , Anti-Dyskinesia Agents/pharmacology , Botulinum Toxins/pharmacology , Electromyography , Follow-Up Studies , Larynx/drug effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...